StreetInsider.com News Articles

Form 8-K Inhibikase Therapeutics, For: Jul 23

Thu, 23 Jul 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260723/26805258.html

Form 8-K Inhibikase Therapeutics, For: Jul 23

Thu, 23 Jul 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260723/26805258.html

FDA grants orphan drug designation to Inhibikase's IKT-001 for PAH

Thu, 23 Jul 2026 08:00:51 -0400

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to its lead product candidate IKT-001, a prodrug of imatinib mesylate, for the treatment of pulmonary arterial hypertension.

The designation was granted by the FDA's Office of Orphan Products Development. The FDA noted that the orphan designation applies to the active moiety of IKT-001, imatinib, rather than a specific formulation. Orphan Drug Designation is granted to investigational therapies intended to treat rare diseases affecting fewer than 200,000 patients in the United States.

The designation provides potential development incentives, including eligibility for tax credits on

FDA grants orphan drug designation to Inhibikase's IKT-001 for PAH

Thu, 23 Jul 2026 08:00:51 -0400

The designation provides potential development incentives, including eligibility for tax credits on

Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH

Thu, 23 Jul 2026 08:00:00 -0400

WILMINGTON, Del., July 23, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), today announced that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation (“ODD”) to its lead product candidate IKT-001, a prodrug of imatinib mesylate, for the treatment of PAH.

"The grant of Orphan Drug Designation for IKT-001 by FDA is another important milestone for Inhibikase and reflects the high unmet medical need among the approximately 50,000 people suffering from PAH in the United States,”

Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH

Thu, 23 Jul 2026 08:00:00 -0400

Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH

Thu, 23 Jul 2026 08:00:00 -0400

Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH

Thu, 23 Jul 2026 08:00:00 -0400

Form 3 Inhibikase Therapeutics, For: Jul 10 Filed by: Kolchinsky Peter

Fri, 17 Jul 2026 17:55:00 -0400

si-local-file:///var/storage/secattach/20260717/26785333.html

Form 3 Inhibikase Therapeutics, For: Jul 10 Filed by: Kolchinsky Peter

Fri, 17 Jul 2026 17:55:00 -0400

si-local-file:///var/storage/secattach/20260717/26785333.html

Form SCHEDULE 13G Inhibikase Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Fri, 17 Jul 2026 17:53:00 -0400

si-local-file:///var/storage/secattach/20260717/26785331.html

Form SCHEDULE 13G Inhibikase Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Fri, 17 Jul 2026 17:53:00 -0400

si-local-file:///var/storage/secattach/20260717/26785331.html

Form 8-K Inhibikase Therapeutics, For: Jul 14

Tue, 14 Jul 2026 08:11:00 -0400

si-local-file:///var/storage/secattach/20260714/26765227.html

Form 8-K Inhibikase Therapeutics, For: Jul 14

Tue, 14 Jul 2026 08:11:00 -0400

si-local-file:///var/storage/secattach/20260714/26765227.html

Inhibikase sells $50M in shares to RA Capital via ATM facility

Tue, 14 Jul 2026 08:00:12 -0400

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced the sale of 25,000,000 shares of its common stock to RA Capital Management through its at-the-market facility, generating gross proceeds of $50 million.

According to a press release, the company said the capital raised, combined with existing cash reserves, is expected to support operations through topline data readout in Part B of its ongoing global Phase 3 IMPROVE-PAH clinical study, subject to the full exercise of outstanding Series A and B Warrants.

The shares were sold under a shelf registration statement on Form S-3, declared effective by the SEC on June 27, 2025, and a prospectus

Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility

Tue, 14 Jul 2026 08:00:00 -0400

WILMINGTON, Del., July 14, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), today announced that it has sold 25,000,000 shares of the Company’s common stock to RA Capital Management through its at-the-market (“ATM”) facility for gross proceeds of $50 million.

The Company expects that the additional capital raised through this financing, together with existing cash reserves, will support operations through topline data readout in Part B of the Company’s ongoing global Phase 3 IMPROVE-PAH clinical study, subject to the full

Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility

Tue, 14 Jul 2026 08:00:00 -0400

Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility

Tue, 14 Jul 2026 08:00:00 -0400

Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility

Tue, 14 Jul 2026 08:00:00 -0400

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 02 Jul 2026 16:01:00 -0400

WILMINGTON, Del., July 02, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced that the Company granted non-qualified stock options to purchase up to an aggregate of 981,243 shares of the Company’s common stock to seven newly-hired non-executive employees under the Company’s 2026 Inducement Equity Plan (the “Inducement Plan”), effective as of June 30, 2026 (the “Effective Date”). The inducement grants were previously approved by the Compensation Committee of the Company’s Board of Directors, as a material inducement to the new employees’ entry into employment with the Company in accordance with Nasdaq

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 02 Jul 2026 16:01:00 -0400

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 02 Jul 2026 16:01:00 -0400

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 02 Jul 2026 16:01:00 -0400

Form 4 Inhibikase Therapeutics, For: Jun 26 Filed by: Canner David

Tue, 30 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260630/26713524.html

Form 4 Inhibikase Therapeutics, For: Jun 26 Filed by: Canner David

Tue, 30 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260630/26713524.html